Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease
- 31 January 2011
- journal article
- Published by Elsevier BV in Neurobiology of Disease
- Vol. 41 (1), 43-50
- https://doi.org/10.1016/j.nbd.2010.08.017
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Neurological Disorders and Stroke (NS053912)
- National Institutes of Health
This publication has 54 references indexed in Scilit:
- Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's diseaseNeurobiology of Disease, 2010
- Early or Late-Stage Anti-N-Terminal Huntingtin Intrabody Gene Therapy Reduces Pathological Features in B6.HDR6/1 MiceJournal of Neuropathology and Experimental Neurology, 2010
- Intrabody Gene Therapy Ameliorates Motor, Cognitive, and Neuropathological Symptoms in Multiple Mouse Models of Huntington's DiseaseJournal of Neuroscience, 2009
- Nicotinamide Restores Cognition in Alzheimer's Disease Transgenic Mice via a Mechanism Involving Sirtuin Inhibition and Selective Reduction of Thr231-PhosphotauJournal of Neuroscience, 2008
- Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington’s diseaseHuman Molecular Genetics, 2008
- N-Terminal Mutant Huntingtin Associates with Mitochondria and Impairs Mitochondrial TraffickingJournal of Neuroscience, 2008
- The Yin-Yang of SirtuinsScience, 2007
- PGC-1α Deficiency Causes Multi-System Energy Metabolic Derangements: Muscle Dysfunction, Abnormal Weight Control and Hepatic SteatosisPLoS Biology, 2005
- Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in BrainScience, 1997
- Nicotinamide treatment in the prevention of insulin‐dependent diabetes mellitusDiabetes/Metabolism Research and Reviews, 1993